We are live on ! Find out more
EC

Elmind Capital Portfolio holdings

AUM $398M
This Fund
S&P 500
This Quarter Est. Return
+51.22%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$339M
AUM Growth
Cap. Flow
+$288M
Cap. Flow %
85.07%
Top 10 Hldgs %
68.55%
Holding
34
New
34
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
URGN icon
26
UroGen Pharma
URGN
$2.22B
$2.34M 0.69%
+100,000
New +$2.17M
IMCR icon
27
Immunocore
IMCR
$1.89B
$2.02M 0.6%
+58,248
New +$2.06M
DSGN icon
28
Design Therapeutics
DSGN
$954M
$1.95M 0.58%
+207,900
New +$1.63M
ENGN icon
29
enGene Therapeutics
ENGN
$128M
$1.9M 0.56%
+210,000
New +$1.68M
ALEC icon
30
Alector
ALEC
$267M
$1.4M 0.41%
+900,000
New +$1.6M
AMLX icon
31
Amylyx Pharmaceuticals
AMLX
$4.14B
$1.35M 0.4%
+112,000
New +$1.52M
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
$1.26M 0.37%
+50,000
New +$1.17M
SUPN icon
33
Supernus Pharmaceuticals
SUPN
$2.57B
$994K 0.29%
+20,000
New +$972K
EWTX icon
34
Edgewise Therapeutics
EWTX
$4.8B
$744K 0.22%
+30,000
New +$602K

Similar funds

Elmind Capital's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Elmind Capital, which disclosed 34 positions worth $339M. Its ten largest holdings account for 69% of the portfolio.

Its largest position is Cogent Biosciences: 1,170,740 shares worth $41.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Elmind Capital's largest Q4 2025 buy was Cogent Biosciences: 1,170,740 shares worth $41.6M.
  • Elmind Capital's ten largest holdings make up 69% of its $339M portfolio in Q4 2025.
  • Elmind Capital disclosed 34 positions in Q4 2025, its first 13F filing on record.

Based on Elmind Capital's 13F filing for Q4 2025, filed 17 Feb 2026.